<DOC>
	<DOCNO>NCT00653120</DOCNO>
	<brief_summary>To compare single-dose bioavailability Propranolol 160 Mg ER capsule Inderal-La</brief_summary>
	<brief_title>Bioavailability Study Propranolol Under Fasting Conditions</brief_title>
	<detailed_description>To compare single -dose bioavailability Par Propranolol 160 Mg ER capsule Wyeth Pharmaceuticals , Inderal-LA , Propranolol fast condition .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Subjects enrol study member community large . The Recruitment advertisement may use various medium type ( E.g . ratio , newspaper , SFBC Anapharm Website , SFBC Anapharm volunteer 's database ) . Subjects must meet follow criterion order include study . Male female , nonsmoker , 18 year age old Capable consent BMI â‰¥ 19.0 &gt; 30.0 kg/ m2 . Subjects follow applies exclude study . Clinically significant illness within 4 week prior administration study medication Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical Sub Investigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 100 140 mmHg , diastolic blood pressure low 60 90 mmHg , heart rate less 60 100 bpm ) screening . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150mL wine , 360 mL beer , 45mL 40 % alcohol ] ) Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screening . History allergic reaction heparin , propranolol , relate drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omerprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interface absorption , distribution , metabolism , excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication counter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive . Difficulty swallow study medication . Use tobacco product 6 month proceed drug administration . Any food allergy , intolerance , restriction special diet , opinion Medical Sub Investigator , could contraindicate subject 's participation study . A depot injection implant drug ( contraceptive ) within 3 month prior administration study medication . Donation plasma ( 500 Ml ) within 7 day drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow . 50mL 300mL whole blood within 30 day , 301 mL 500 ml whole blood within 45days 500 mL whole blood within 56 day prior drug administration.. History bronchial asthma bronchospastic disease . History known presence cardiogenic shock , sinus bradycardia , WolffParkinson White Syndrome , congestive heart failure angina . Clinically significant history diabetes . Clinically significant history hyperthyroidism . Breast feeding subject . Positive urine pregnancy test screening . Female subject childbearing potential unprotected sexual intercourse non sterile male partner ( i.e . male ahs sterilize vasectomy al least 6 month ) within 14 day prior study drug administration . Acceptable method contraception : Intrauterine contraceptive device ( place al least 4 week prior study drug administration ) Condom diaphragm . + spermicide Hormonal contraceptive ( start al least 4 week prior study administration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Bioequivalence , Propranolol ER capsule , fast</keyword>
</DOC>